Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aeterna Zentaris initiates phase I study for anticancer drug
The phase I trial is being conducted in the US and will include up to 50 patients with advanced solid tumors and lymphoma who have either failed standard
The phase I trial is being conducted in the US and will include up to 50 patients with advanced solid tumors and lymphoma who have either failed standard
The nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist NBI-56418 was assessed over 12 weeks in women with endometriosis, a condition which happens when tissue similar to the endometrial lining
The biopharmaceutical company said that the trial endpoints were the time to systemic disease progression and the change in velocity of Prostate Specific Antigen levels. Neither endpoint was
The committee evaluated the first ten patients enrolled to the phase II trial of PDX in patients with relapsed or refractory peripheral T-cell lymphoma who had completed one
The agreement will use Ablynx’ Nanobodies, a novel class of therapeutic proteins which combine the beneficial features of conventional antibodies, with desirable properties of small-molecule drugs. In addition,
The acquisition includes brand names such as Carbolevure, Revitalose, Balsoclase and Toclase, representing annual sales of approximately $18 million. UCB will continue to manufacture and supply some of
Caremark said that the proposal from Express Scripts risks losing customers and includes questionable assumptions with regard to synergies. The company also asserted that the offer is a
Merck Serono will be combined with the current Merck Ethicals division with its headquarters in Geneva, Switzerland. Merck said that the division will create a leading global supplier
Peptech will receive 90% of the funds within the next few days, while the remaining 10% will be held in escrow for one year. Peptech CEO Dr John
Researchers at the National Cancer Institute in Bethesda have found that higher body mass index (BMI) correlated strongly with increased risk of death from prostate cancer. However, no